

Patrizia Suppressa

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3902369/patrizia-suppressa-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

15
papers

311
citations

8
h-index

17
g-index

17
ext. papers

384
ext. citations

3.9
avg, IF

2.5
L-index

#	Paper	IF	Citations
15	Abdominal obesity negatively influences key metrics of reverse cholesterol transport. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2021 , 1867, 159087	5	0
14	AST to Platelet Ratio Index (APRI) is an easy-to-use predictor score for cardiovascular risk in metabolic subjects. <i>Scientific Reports</i> , 2021 , 11, 14834	4.9	7
13	Minimal portosystemic encephalopathy: A new nosological entity in patients with hereditary haemorrhagic telangiectasia. <i>European Journal of Internal Medicine</i> , 2021 , 90, 43-48	3.9	
12	Characterization of epidemiological distribution and outcome of COVID-19 in patients with hereditary hemorrhagic telangiectasia: a nationwide retrospective multi-centre study during first wave in Italy. <i>Orphanet Journal of Rare Diseases</i> , 2021 , 16, 378	4.2	1
11	European Reference Network for Rare Vascular Diseases (VASCERN) position statement on cerebral screening in adults and children with hereditary haemorrhagic telangiectasia (HHT). <i>Orphanet Journal of Rare Diseases</i> , 2020 , 15, 165	4.2	14
10	Gender, BMI and fasting hyperglycaemia influence Monocyte to-HDL ratio (MHR) index in metabolic subjects. <i>PLoS ONE</i> , 2020 , 15, e0231927	3.7	4
9	Safety of thalidomide and bevacizumab in patients with hereditary hemorrhagic telangiectasia. <i>Orphanet Journal of Rare Diseases</i> , 2019 , 14, 28	4.2	45
8	Efficacy of Lomitapide in the Treatment of Familial Homozygous Hypercholesterolemia: Results of a Real-World Clinical Experience in Italy. <i>Advances in Therapy</i> , 2017 , 34, 1200-1210	4.1	39
7	A case of sarcoidosis with isolated hepatosplenic onset and development of inflammatory bowel disease during recovery stage. <i>Autoimmunity Highlights</i> , 2017 , 8, 6	3.7	
6	Hepatic angiodynamic profile in paediatric patients with hereditary haemorrhagic telangiectasia type 1 and type 2. <i>Vasa - European Journal of Vascular Medicine</i> , 2017 , 46, 195-202	1.9	4
5	Liver involvement in hereditary hemorrhagic telangiectasia: can breath test unmask impaired hepatic first-pass effect?. <i>Internal and Emergency Medicine</i> , 2012 , 7, 323-9	3.7	8
4	Low dose intravenous bevacizumab for the treatment of anaemia in hereditary haemorrhagic telangiectasia. <i>British Journal of Haematology</i> , 2011 , 152, 365	4.5	15
3	Liver involvement in a large cohort of patients with hereditary hemorrhagic telangiectasia: echo-color-Doppler vs multislice computed tomography study. <i>Journal of Hepatology</i> , 2008 , 48, 811-20	13.4	68
2	DHPLC-based mutation analysis of ENG and ALK-1 genes in HHT Italian population. <i>Human Mutation</i> , 2006 , 27, 213-4	4.7	32
1	Health-related quality of life in a rare disease: hereditary hemorrhagic telangiectasia (HHT) or Rendu-Osler-Weber disease. <i>Quality of Life Research</i> , 2004 , 13, 1715-23	3.7	74